As Jan mentioned, we have made a significant improvement to our recruitment rate. So we have accelerated our recruitment rate from approximately 2 to 5 patients per month despite COVID. And also, we are expecting that COVID is lessening. And assuming that, that happens, the rate can further increase to at least 7 patients on average per month in late spring. Where did that improved rates come from? We have significantly improved the management of our CRO and also retained specialized firms to further improve our recruitment. We have converted our PARADIGME trial from a 2-arm into a single-arm trial. And we also introduced simplification in the execution for our clinicians. We have very good, positive safety data set from the interim analysis, and that also allowed us to broaden our inclusion criteria. We are now able to include patients with lower platelet counts and autologous stem cell transplantation. That pool of eligible patients increase, depending by country, between 30% and 50%. And the analysis of interim data showed that number of patients to complete PARADIGME can be reduced. So we were able to present that to the health authorities, and we can reduce the number of patients to 120. And that means we only have to have another 47 patients to go to finalize PARADIGME for the regulatory submission. With all of that, we reiterate our target to report preliminary 3-month top line data in the second half of this year. Let me go in more detail through the highlights. We have now 73 patients enrolled as of yesterday. And to remind everyone, we had 59 patients as of November 18. That means we have 14 patients enrolled in the last 3 months with only 3 patients from August to November 2020. So there, you can see that all of our actions really come to [facilitation], and we are very confident that we can even go higher. Our protocol amendments have now been implemented in all 24 countries. Last month, we're approving it -- last week. The final patients have been enrolled in our second cohort for Archer-1 and our second line Betalutin trial and also in the LYMRIT 37-05 phase where we are treating DLBCL patients. The preliminary data readout is expected in the first half of this year. Both trials now have been paused pending the analysis of data and the evaluation of further plans and development. We also were able to publish in Journal of Nuclear Medicine the results of our preclinical studies demonstrating that Betalutin reverses tumor resistance to rituximab in non-Hodgkin lymphoma disease models. So all of that is really very, very positive, and we are on the right track. Betalutin has a compelling, unique and differentiated value proposition for non-Hodgkin lymphoma patients. A short reminder, we have an anti-CD37 antibody. CD37 is highly expressed on B cells. We do have lutetium with a half-life of 7 days as a radioactive compound. And the mechanism of action of our antibody drug conjugate is internalization and cell death and, very important, the crossfire effect of lutetium, which gives us really very, very good results. Now the key benefit, especially during the pandemic, we should not forget and our elderly patients. WE ONLY HAVE A SINGLE-DOSE TREATMENT, SO NONE OF OUR COMPETITORS HAVE THIS. We have a durable response in elderly and heavily pretreated patients. Our safety profile is very good. We have a predictable and manageable side effect burden. And very importantly, most treatments today are anti-CD20 treatment, and WE DO HAVE AN ALTERNATIVE TARGET TO CD20, which is suitable for rituximab refractory patients. Now as we promised when I took over in February that we wanted to revise our clinical strategy and that we are focusing on PARADIGME, so that is what really happened over the last year. So we brought forward PARADIGME. And PARADIGME is our first-to-market in the trial, so the indication is third line relapsed/refractory follicular lymphoma. We are, of course, together with the data out of Archer-1 and LYMRIT 37-05, which I mentioned they are finalized and we are analyzing the data, we're looking at all of that data together to really realize the optimal strategy to advance in earlier lines. And since we do have also pretty good results in marginal zone lymphoma, we're also looking on the opportunity how to move ahead with marginal zone lymphoma. Now going shortly to Part A. Sorry for everybody who has heard that several times, I think it's still a very impressive story. So what you can see here on the waterfall diagram is the amount of shrinkage of the tumor size. What you can see there in our 74 patients which we had in the 37-01 Part A trial that about 90% of the patients have a shrinkage or reducing in tumor size. And slightly other description is that we have an overall response rate of 67% and 24% of CR in rituximab refractory patients. AS I MENTIONED, THESE ARE REALLY THE ONES WHICH ARE SUFFERING MOST FROM NOT HAVING ANY THERAPY AVAILABLE. Our medium response rate for all responders is more than a year. AND EVEN MORE THAN 2.5 YEARS, WE DO HAVE FOR OUR COMPLETE RESPONDERS. So that's a very impressive result with progression-free survival of around 9 months. Now that is also important for how we position Betalutin in the market. As Jan mentioned, we are now preparing it. I would like to remind everyone our patient characteristics is that we have elderly patients. The median is 68 years old, and there is no huge difference between Part A and Part B. They've been heavily pretreated with advanced-stage disease. And that is also pretty similar between Part A and Part B. So overall, we have a very good safety data set and efficacy data set in that patient population. Betalutin was also very well tolerated. That is why we also can now treat patients with lower platelets and autologous stem cell transplantation. Interim analysis, as mentioned by Jan, we had it in July last year. We had before a 2-arm trial with the lower dose and the higher dose. So the lower dose was the 15 MBq per kilogram Betalutin and the pretreatment of the cold antibody with 40 milligrams flat of lilotomab, and the higher dose arm was 20 MBq per kg and Betalutin and 100 mg per meter square lilotomab. So these were the 2 arms. And the Safety Review Committee looked at all of the data in very much detail and recommended to go ahead with the 40/15 arm. As mentioned, we have 73 patients enrolled as of yesterday. And the trial reduced to 120 patients with 47 patients to go. We have 95 sites opened in 24 countries. We have promised that our #1 priority (inaudible) is the improving of trial execution. Let me recap a little bit what we have done. So the protocol amendment, as we mentioned already, is now approved in all 24 countries. The broadening of the inclusion criteria has increased the pool size by 30% to 50% depending on the country. The decision to make PARADIGME a single-arm trial led to a reduction in patient numbers needed to complete PARADIGME for BLA filing. 47 patients are now needed to finalize it. The site-specific action plan has been implemented. Senior leadership at NANO and our CRO are deeply involved in continuous monitoring of the site performance metrics, which are also increasing significantly. The CMO is hosting virtual meetings with trial investigators and the teams to promote PARADIGME. So Christine is very active here. She had more or less every PI on the call, and they are appreciating that very much. The specialist firms we have appointed are there to focus on further improving our rate of recruitment, including targeted social media campaigns. The major focus currently is North America and then, particularly, the U.S. There's also some other effects from our competitors. The 3 trials, our competitors have been finalized. And the bispecific -- one bispecific antibody trial is on clinical hold. So that also might give us a few different patients. And very important also here is the vaccination rollout is expected to reduce restrictions imposed by COVID-19. And as you know, our patients are, on average, 68 years old. They are in the group which needs to be protected. So from that point, it is very important for all patient population that the vaccination is going on very fast. Our regulatory strategy to gain rapid approval. BLA filing with the FDA for accelerated approval based on PARADIGME data and initiation of confirmatory Phase III trial. So that is important. We will go ahead with our Phase IIb PARADIGME trial. We do have orphan drug designation for third-line follicular lymphoma granted in the U.S. and in the EU. We do have fast track granted for both, for example, marginal zone. And in the U.K., we do have also the promising innovative medicine status. And of course, we are always exploring other routes to bring Betalutin faster to our patients. Now coming to the positioning of Betalutin, going to Slide 16. What you can see here is what we mentioned before as well. And it's a unique product profile of Betalutin which positions us as the treatment of choice for elderly and frail patients, which are approximately 70% of all third-line follicular lymphoma patients. And if you progressed at a very early stage in the third line, you have great medicines like the stem cell transplantation, which I mentioned, or also the CAR-T, which goes to approval as they are looking with very promising results, very expensive. They do have high side effect, and only a very few patients are eligible for it. https://finance.yahoo.com/news/edited-transcript-norn-ol-earnings-073000907.html